交易 Immunovant Inc - IMVT 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.11
• 長倉隔夜倉息調整: -0.02149%
• 短倉隔夜倉息調整: -0.00074%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 23.59
• 開倉: 23.3
• 1 年變化: 24.07%
• 日區間: 22.76 - 23.79

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.